The Anterior Cingulate Cortex (ACC, Brodmans Area 24) is implicated in the pathogenesis of schizophrenia due to its normal functions and connectivity together with reports of structural, morphological and neurotransmitter aberrations within this brain area in the disease state. Two-dimensional gel electrophoresis (2DE) was employed to scan and compare the ACC gray matter proteomes between schizophrenia (n = 10) and control (n = 10) post-mortem human tissue. This proteomic approach has detected 42 protein spots with altered levels in the schizophrenia cohort, which to our knowledge is the first proteomic analysis of the ACC in schizophrenia. Thirty nine of these proteins were subsequently identified using mass spectrometry and functionally classified into metabolism and oxidative stress, cytoskeletal, synaptic, signalling, trafficking and glial-specific groups. Some of the identified proteins have previously been implicated in the disease pathogenesis and some offer new insights into schizophrenia. Investigating these proteins, the genes encoding these proteins, their functions and interactions may shed light on the molecular mechanisms underlying the heterogeneous symptoms characteristic of schizophrenia.
Introduction
The Anterior Cingulate Cortex (ACC, Brodmans Area 24, BA24) is implicated in the pathogenesis of schizophrenia. Schizophrenia commonly involves abnormalities in functions attributed to the ACC including emotion, affect 1 and cognition, such as executive control 2 and attention. 3 Abnormal activation of the ACC during hallucinations 4 and task performances in schizophrenia patients 1, 5, 6 further support a role of BA24 in the positive, negative and cognitive symptoms of the disease.
Schizophrenia has presented with few characteristic structural or morphological pathologies. Within the ACC there is an observed gray matter volume reduction 3 and accordingly, reduced laminar thickness, 7 a reduction of pyramidal neurons in the deeper lamina 8, 9 and smaller pyramidal neuron size. 7, 8 In layer II of the ACC vertical fibres are increased 10 and small neurons decreased. 9 These structural and morphological changes within subsets of schizophrenia patients point to a dysfunction within the ACC in the disease pathology.
The various symptoms of schizophrenia are thought to be the manifestation of abnormal dopamine, glutamate and GABAergic neural circuitry involving multiple brain regions. 11 Within the ACC there is an observed hyper-dopaminergic activation of GABA cells, 12 an increase in glutamatergic neurons from the thalamus and amygdala and a reduction in the number of GABA cells co-expressing NMDA glutamate receptors in schizophrenia. 13, 14 These findings, together with a reported increased GABA A binding and a depletion of nonpyramidal neurons in layer II of the ACC, 15 suggest an overabundance of glutamate excitation and reduced dopamine inhibition on GABA neurons in layer II of the schizophrenia ACC. This is thought to result in enhanced glutamatergic transmission from the ACC to connecting brain areas. Hyper-glutamatergic activity is also believed to induce an excitotoxic response within the ACC which has various consequences including oxidative damage. 16 While the literature shows pathology in the structure, function and circuitry of the ACC in schizophrenia, this brain region is not well characterized in the disease state. Proteomics, with the ability to investigate the translation of genomic information together with co-and post-translational modifications, 17 offers an approach to studying the global changes in protein expression and modification caused by neuropathologies such as Alzheimer's Disease (AD), Down Syndrome (DS) and schizophrenia. Previous findings of proteomic investigations into schizophrenia include various proteins associated with metabolism and oxidative stress to be differentially expressed in the prefrontal cortex (PFC) in the disease state relative to controls, 18 proteins previously implicated in schizophrenia as well as some novel proteins to be altered in the frontal cortex, 19 and four of 18 altered proteins in the schizophrenia hippocampus mapping to chromosome 6q. 20 In addition, a proteomic study investigating the cerebrospinal fluid (CSF) in schizophrenia identified 54 different gene products, 17 leading to new and refined hypotheses into the molecular mechanisms underlying this disease.
Using a proteomic method the current study aims to isolate and identify proteins with altered levels within the ACC gray matter in schizophrenia compared to the healthy ACC and to elucidate potential molecular mechanisms of this brain region in schizophrenia based on these findings.
Materials and methods

Human brain tissue
Fresh frozen post-mortem human brain tissue from the gray matter of the ACC (BA24) of 10 nonpsychiatric controls and 10 schizophrenia individuals was obtained from the NSW Tissue Resource Centre (University of Sydney, NSW, Australia). Punch holes were taken from the ACC at the level of the rostrum of the anterior cingulate gyrus between points at which the gyrus curves above and below the corpus callosum. 21 The diagnosis of schizophrenia was confirmed using the Diagnostic Instrument for Brain Studies (DIBS) and all cases fulfilled the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) of the American Psychiatric Association for schizophrenia. 22 Cases with a recent history of coma or any other medical illness which may affect the agonal state of the patient were ruled out. Control cases had no history of major psychiatric illness. Cases were matched for age, sex, brain hemisphere, pH and post-mortem interval (PMI) and ethnicity where possible. All cases are Caucasian/ Australian with eight males and two females in each group. Details of each are listed in Table 1 . Additionally the type of schizophrenia diagnosed, duration of illness and antipsychotic dose, expressed in mg/day (Table 2) . Approval from the Central Sydney Area Health Service (Protocol Number X03-00285) was obtained for the use of human post-mortem brain tissue in this study.
Sample preparation
Sample preparation and two-dimensional gel electrophoresis (2DE) methodology was according to Alexander-Kaufman et al. 23 Briefly, 0.04-0.07 g of crude ACC fresh frozen tissue was placed in Buffer 1 (7 M Urea, 2 M Thiourea, 1% C7bZO, 40 mM Tris). Sample suspensions were sonicated 3 Â 10 s at 40% intensity and centrifuged at 14 000 g for 20 min at 151C. The supernatant was reduced and alkylated in 5 mM tributylphosphine (TBP) and 1 M acrylamide monomer at room temperature for 2 h. The reaction was quenched by adding 10 mM DTT followed by 20 mg citric acid to adjust pH to approximately pH 6.0. Samples were precipitated using five volumes of room temperature acetone for 10 min and centrifuged at 3500 g for 15 min at 151C. The pellet was air dried for 5 min and resuspended in Buffer 2 (7 M urea, 2 M thiourea, 1% C7bZO).
Two-dimensional gel electrophoresis
Protein concentration was determined by the Bradford method 24 using a complex protein mixture from human brain as a standard. The 10 schizophrenia and 10 control sample tissues were used to perform duplicate 2DE analyses, providing a total of 20 gels for each of the disease and control groups. Precast immobilized pH gradient strips (IPG, 11 cm, pH 3-10, Proteome Systems, North Ryde, Australia) were passively rehydrated in 200 mg sample protein extract for 6 h at room temperature. In the first dimension, rehydrated strips were focussed using an ElectrophoretIQ 3 isoelectric focusing system (Proteome Systems) for a total of 120 kVh. IPG strips were reduced, alkylated and detergent exchanged using SDS equilibration buffer (Proteome Systems, 20 min) and loaded onto precast SDS-PAGE gels (GelChipt 2D, 6-15%, 10 Â 15 cm; Proteome Systems) for second dimension molecular mass separation using the ElectrophoreticIQ 3 system (50 mA/gel, 151C for 90 min).
Image acquisition and analysis Gels were fixed in solution containing 25% (v/v) methanol and 10% (v/v) acetic acid for 1 h and stained using colloidal Coomassie Blue for spot visualization. Gels were scanned using a transmissive, flatbed scanner (UMAX) and analysed using Phoretix 2D Expression software (Nonlinear Dynamics, Newcastle-upon-Tyne, UK). Following background subtraction and volume normalization of all gels, average gels were created for each group to assist comparison and reduce within group variations. Averaging parameters were set at 70%, therefore for a protein spot to appear in the averaged gel it must be present in 70% of all gels within a group. One-way Analysis of Variance (ANOVA) statistical tests were used to reveal statistically significant protein expression differences between the two groups. Protein spots with a mean n-fold change between schizophrenia and control ACC gray matter gels of (7) 1.5 were excised for identification by mass spectrometry. For protein identification, approximately 0.8 ml of the peptide mixture was spotted onto a target plate and covered with the same volume of matrix solution (a-cyano-4-hydroxy cinnamic acid (Sigma), 8 mg/ml in 70% (v/v) acetonitrile/1% (v/v) formic acid) and allowed to air dry. In several cases, peptides were concentrated and desalted using C 18 Perfect Pure Tips (Eppendorf). Tips were activated with acetonitrile and washed with 5 Â 10 ml of 1% (v/v) formic acid. The peptide mixture was then bound and aspirated five times through the column and bound peptides washed with 5 Â 10 ml of 1% formic acid. Peptides were eluted in 0.8 ml of matrix solution directly onto a MALDI-TOF target plate. Peptide mass maps of tryptic peptides were generated by matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) using an Applied Biosystems Q-STAR Pulsar with MALDI source (APAF, University of Sydney). Mass calibration was performed using trypsin autolysis peaks, 2211.11 and 842.51 Da as internal standards.
Mass spectrometry
Database searching
Data generated from peptide mass mapping (PMM) of each spot were used to perform searches of the SWISS-PROT, NCBI and TrEMBL databases using the programs Aldente (www.expasy.ch) and MASCOT (www.matrixscience.com). Identification parameters include peptide mass accuracy within 0.12 Da, one possible missed tryptic cleavage per peptide and with methionine sulfoxide and cysteine-acrylamide modifications checked. Identifications were based on the observed pI and M r (kDa) of the matched protein, the number of matching peptide masses and the total percentage of the amino acid sequence that those peptides covered, in comparison to other database entries. Generally, a peptide match with at least 30% total sequence coverage was required for confidence in identification, but very low-and high-mass protein, and those resulting from protein fragmentation may not always meet the criterion. For searches performed using MASCOT, E-value and Score, as well as matching peptides and sequence coverage, were used to determine matches.
Results
Two-dimensional gel electrophoresis comparison of normal and schizophrenia anterior cingulate cortex gray matter
Significantly altered proteins in the ACC gray matter of schizophrenia post mortem tissue (change in mean spot abundance of 7 > 1.5 fold) was determined from the averaged gel of each group (20 gels each per group). In all, 648 and 532 spots were present in more than 70% of the control and schizophrenia group, respectively. In total more than 97% of all spots were matched to the reference gel, allowing excellent comparison between the two groups. Changes in the relative abundance of 42 protein spots were identified in the schizophrenia ACC gray matter (7 > 1.5 fold difference, P < 0.05, ANOVA) compared to the control group, as described in Table  3 . Twenty-two exhibited an increase in the disease group with six having more than a two-fold increase. Eight protein spots were decreased with three of these changed two-fold and the other five changed by more than 60%. Twelve protein spots were absent in the schizophrenia group when compared to the control group. An image highlighting the changed expression of particular spots between the two groups is illustrated in Figure 1 .
Identification of altered proteins in the schizophrenia anterior cingulate cortex gray matter Thirty-nine of the 42 protein spots present at altered levels in the schizophrenia ACC gray matter were identified using MALDI-TOF MS (Table 4 ). The 39 protein spots represent 36 unique genes. Three proteins (isocitrate dehydrogenase subunit a, actinlike protein 3 and peptidyl prolyl cis-trans isomerase) were identified in more than one spot, suggesting changes in post-translational modifications of these proteins may occur (Figure 2) . The protein spots which have not been identified (spot number 2468, 202 and 1138) did not generate high quality MS spectra and as such may be present in too little abundance for MS analysis.
Proteins appearing with altered levels in the schizophrenia ACC can be functionally classified as synaptic, signalling, metabolic and oxidative stress, trafficking, cytoskeletal and glial-specific proteins (Table 4) . Eight proteins altered in the disease group are involved in energy metabolism within the brain, with seven spots reduced or absent and one increased. A further four proteins involved in oxidative stress are altered in the schizophrenia ACC gray matter. One is increased by more than two-fold, while two are reduced in schizophrenia. Nine cytoskeletal proteins are changed between the two case groups, most of which are upregulated more than 60%. Two proteins associated with neuronal synapses have elevated levels while another is absent in the patient group. Five proteins play a role in signalling and are all increased in the ACC gray matter of schizophrenia patients compared to controls, with three having > two-fold increase.
Three proteins associated with protein trafficking and four located within glial cells are altered in the schizophrenia ACC gray matter. A further three proteins were identified, yet have no known function (summarized in Table 4) .
Post hoc statistical analysis (Pearson correlation) was performed on the normalized volume of all altered protein spots of each sample to determine the effects of pH, PMI, age and duration of illness on protein abundance in 2DE gels. As the Cpze antipsychotic dose equivalent for most patients was a large range (Table 2) , no statistical analysis could be performed on the results. Three spots were correlated with pre/post mortem factors: The normalized volume of DRP2 and DDAH-1 correlated with pH (r 2 = 0.293 and 0.301; P = 0.017 and 0.015, respectively) while the level of Acetyl CoA acetyltransferase correlated with PMI of the samples (r 2 = 0.462, P = 0.03). Tissue pH has been described as an important factor for mRNA and possibly protein stability. 25, 26 Where reduced pH is associated with reduced or absent mRNA. Therefore, the altered abundance of DDAH-1 and DRP2 may be attributed to differences in pH. Similarly, the level of some proteins have changed with prolonged PMI, showing altered levels or truncation on 2DE, with most changes appearing at a PMI of 24 h or later. 26, 27 Therefore, the level of Acetyl CoA acetyltransferase, a protein involved in glucose metabolism in times of oxidative stress, may not be due to the disease itself.
Discussion
Two-dimentional gel electrophoresis allows only the study of soluble proteins in relatively high abundance and in a specific pH range. Despite these limiting factors, 42 protein spots were identified as being present at significantly different levels in the ACC gray matter in schizophrenia relative to controls. Of the 39 identified proteins, changes in the level of Proteomics of schizophrenia anterior cingulate cortex D Clark et al three correlate with pre-and post-mortem factors. The remaining 36 altered proteins were classified by their predicted functions. These classes include metabolic and oxidative stress (n = 11), cytoskeletal (n = 9), synaptic (n = 3), signalling (n = 4), trafficking (n = 3) and glial-specific proteins (n = 4). Many of the proteins differentially expressed in this study have been previously proposed to be associated with the disease. SNAP-25, 28 a synaptic-related protein, metabolic proteins NADH oxidoreductase 29 and CKB, 30 a free radical scavenger SOD, 31 a glial-specific protein GFAP 19 and a trafficking protein, HSP70, 32 are all reported to have altered activity and/or expression levels in schizophrenia. Proteins found to be altered in the ACC gray matter in this study may (a) have a role in schizophrenia and (b) be potential markers of the disease. Based on these results a hypothesis may be formed leading to a more focussed direction for future studies.
Metabolism
Five spots appearing downregulated in the schizophrenia ACC gray matter were identified as enzymes involved in all stages of cellular respiration. These are fructose bisphosphate aldolase C (FBA-C, absent in schizophrenia), citrate synthase (absent in schizophrenia), two spots corresponding to isocitrate dehydrogenase (À1.692 and absent), and NADH ubiquinine oxidoreductase (À1.944). FBA-C, a glycolytic enzyme, has previously been implicated in schizophrenia with increased levels in the frontal cortex proteome of schizophrenia patients, 19 reduced levels in both the gray and white matter of the PFC proteome 18 and an increased immunoreactivity in schizophrenia CSF. 33 Citrate synthase and isocitrate dehydrogenase form a part of the citric acid cycle. The two spots reduced in the schizophrenia group corresponding to isocitrate dehydrogenase are possibly different isoforms of this protein. Isocitrate dehydrogenase was previously reported to have depleted mRNA levels in the hippocampal dentate gyrus of schizophrenia sufferers. 34 NADH ubiquinone oxidoreductase, or Complex 1, is the first enzyme complex in the electron transport chain. In the ACC gray matter, the 13 kDa-B subunit of Complex 1 is decreased 1.944 fold in schizophrenia compared to controls. This is in corroboration with previous studies, which report lower activity of complex 1 in the temporal cortex, basal ganglia 29 and in platelets of patients with residual schizophrenia 35 as well as diminished mRNA levels in the dentate gyrus 34 and reduced level of protein in both the gray and white matter proteomes of the PFC in schizophrenia. 18 Dror et al. further found complex 1 activity to be associated with psychotic symptomatology. 35 In addition, the gene encoding the 13 kDa-B subunit, located on chromosome 7, has also previously been associated with schizophrenia. 36, 37 The reduced abundance of enzymes involved in each stage of cellular respiration suggests depleted glucose metabolism leading to oxidative stress of the ACC in the pathology of schizophrenia.
In addition to proteins involved in glucose metabolism present in altered levels in the schizophrenia ACC gray matter proteome, creatine kinase B (CKB, þ 1.982) and creatine kinase ubiquinone mitochondrial protein (CK-Mit, absent), involved in brain metabolism, were also altered in the disease. Located in the cytoplasm of glial cells 38 and GABAergic interneurons, 39 CKB reversibly catalyses the transfer of phosphate between ATP and various phosphogens such as creatine phosphate, 40 important in the brain for habituation, spatial learning and behaviour. 41 Cells with high CKB expression are known to be resistant to neurological insults, such as glucose and oxygen deprivation 39 and as such the increased CKB expression in the ACC gray matter may protect cells from oxidative damage observed in the disease state. However, activity of CKB is thought to be reduced in the frontal cortex, anterior and posterior cingulate, hippocampus and cerebellum in schizophrenia. 42 These conflicting data may be due to the location of CKB to subsets of cells 38, 39 which are differentially affected in schizophrenia. CK-Mit, located on the membrane of neurons is involved in the generation of ATP 43 and possibly glutamate filling into synaptic vesicles. 39 A spot corresponding to CK-Mit was not visualized in a sufficient amount of the schizophrenia ACC gray matter gels, in agreement with the literature detailing a reduced level of CK-Mit in post-mortem schizophrenia tissue. 30, 42 This data suggest neuronal energy depletion, possibly glutamatergic. Synaptic filling of glutamatergic cells would also be adversely affected by a loss of CK-Mit in the ACC in schizophrenia.
A further three proteins with significantly altered levels in the ACC gray matter, superoxide dismutase (SOD, þ 1.827), hydroxyacylglutathione hydrolase (Gly II, À1.563) and annexin A1 ( þ 1.506) are involved in the oxidative stress response. SOD destroys radicals, protecting against neuronal degeneration induced by glutamate, 44 oxyradical injury 45 and ischaemic brain damage. 16 The levels of SOD have been consistently found to be high in chronic schizophrenia patients 46 or low in neuroleptic naïve first-episode patients. 31 The vulnerability of striatal neurons to excitatory neurotransmission was exacerbated by neuroleptics, 47 suggesting elevated SOD levels and activity may be in part attributed to neuroleptics. However, neuroleptics acting at dopamine D2 receptors augment the synaptic release of glutamate, resulting in neural degeneration and increased production of oxyradicals thereby causing expression and/or activity of SOD to increase. Gly II of the glyoxylase pathway, catalyses methylglyoxal, a toxic glycolytic byproduct. When this pathway is impaired or inhibited methylglyoxal accumulates to toxic levels resulting in initially reversible, later irreversible modifications to proteins. 48 Since Gly II is decreased in the schizophrenia ACC gray matter, increased methylglyoxal activity may cause irrever- Taken together these findings suggest normal cellular respiration is depleted in the ACC gray matter in schizophrenia with the consequent production of oxidative byproducts and an increased molecular response to oxidative stress. These findings are in agreement with the literature detailing aberrant metabolic activity within this brain region in schizophrenia at rest, as well as during cognitive task performances. 49, 50 Cytoskeletal proteins Nine proteins associated with the cytoskeleton were present at altered levels in the schizophrenia ACC gray matter, however, only a few have previously been associated with pathogenesis. The cytoskeleton, composed of microtubule and actin, plays a role in a wide variety of functions in cells, affecting their shape and motility, organization of the spatial distribution of organelles in the cytoplasm and chromosome segregation during mitosis and integration of transmembrane signals. Thus the behaviour of microtubules is influenced by many different microtubule interacting proteins. 51 Tubulin a-6, reduced in the ACC gray matter in schizophrenia, together with dynamin 1 and stathmin, both increased in the disease group, are associated to the microtubule cytoskeleton. A major constituent of microtubules, tubulin also serves as an attachment site for binding vesicles or plasma membranes to the cytoplasmic microtubules and interacts with various membrane proteins such as metabo-glutamate receptors. 51 Dynamin 1 is a forceproducing protein functioning in receptor mediated endocytosis and synaptic vesicle recycling in nerve terminals. 52 Stathmin is involved in the regulation of the microtubule filament system 51 and is important in maintaining normal neurons and glia, since stathmin gene knockout mice develop axonopathy. 53 Previously, stathmin was found to have altered expression in MK-801 treated rats, a glutamategic schizophrenia animal model. 53 Molecules that interact with stathmin include HSP70 and G proteins, 54 and as such altered levels of these proteins may also be related to cytoskeletal abnormality. Further investigations are necessary to elucidate the precise role of stathmin and the microtubule cytoskeleton in schizophrenia.
In addition to proteins involved with the microtubule, three altered spots in the ACC gray matter (two spots of actin-like protein 3 and annexin A5) correspond to the actin cytoskeleton. Actin-like protein 3 is part of a complex implicated in the control of actin polymerization in cells. One of the actin-like 3 protein spots was increased while the other was not visualized in the ACC gray matter in the schizophrenia average gel, suggesting the addition or subtraction of a chemical post-translational modification, resulting in a pI shift. Annexin A5, increased in the ACC gray matter in schizophrenia, is a calcium and phospholipids binding protein which interacts with actin and is though to participate in membrane (re)organization and vesicle trafficking. Our findings implicate the actin cytoskeleton in the schizophrenia pathology within the ACC for the first time. The cytoarchitectural variations found in this study may trigger the structural changes observed in the ACC in schizophrenia 3, 8, 9 and warrant further investigations into the molecular mechanisms and effects of an altered cytoskeleton in the disease state.
Synaptic proteins
Three proteins involved in the synapse had altered abundance in schizophrenia (N-ethylmaleimide sensitive factor (NSF), þ 1.603, SNAP-25, þ 1.721 and serine/threonine protein phosphatase 1 (PP1), absent in schizophrenia), adding further support to the well documented hypothesis of neurotransmitter system aberrations involving the ACC.
7,9-15 N-ethylmaleimide sensitive factor is involved in the docking and fusion of synaptic vesicles with the plasma membrane. 55 Previously, NSF protein expression was shown to increase in the schizophrenia PFC (BA9) gray matter proteome, 18 while the gene encoding NSF, located on 17q21, was decreased (BA46) in subjects with schizophrenia compared to controls. 56 However, in a subsequent study, the decrease in the NSF gene was not significant. 57 A Western Blot analysis also failed to reproduce findings of an alteration in the NSF levels in the PFC (BA9, 10 and 46). 58 The discrepancy between these studies may be due to the location of NSF within subsets of cells differentially affected in schizophrenia and/or to specific anatomical locations in schizophrenia. Alternatively, NSF may be specifically altered in the gray matter, 18 an affect which could be overshadowed by investigating both gray and white matter together. The precise role of NSF in schizophrenia remains to be elucidated.
The catalytic subunit of protein phosphatase 1 a (PP1c) is absent in the schizophrenia gray matter ACC proteome. Located in both neurons and glia 59 PP1 regulates many cellular functions such as neurotransmission. 60 Regulation of PP1 is by phosphorylated DARPP-32 (pDARPP-32), a potent inhibitor of PP1. The phosphorylation of DARPP-32 occurs through activation of dopamine, serotonin and glutamate receptors. Amphetamine and LSD, agonists of dopamine and serotonin receptors, respectively, and PCP a glutamate receptor antagonist all induce psychotomimetic states in experimental animals which closely resemble symptoms of schizophrenia. 61 These effects are thought to be mediated through a common signalling pathway, which includes inhibition of PP1 by pDARPP-32. 62 Furthermore increased activation of each or any of these neurotransmitter receptors may increase inhibition of PP1 leading to enhanced psychosis.
These findings of modified synaptic proteins, together with an increase of SNAP-25 in the ACC gray matter proteome, show aberrant neuronal components in the disease state. These changes may underlie the abnormal ACC circuitry via the neurotransmitters dopamine, glutamate and GABA in the pathophysiology of schizophrenia.
Signalling proteins
This proteomic analysis revealed four proteins involved in cellular signalling increased in the schizophrenia group. These were G protein ( þ 2.615), phosphatidylethanolamine-binding protein (PEBP, þ 2.376), dihydropyrimidinase-related protein 1 (DRP-1) and EH domain containing three protein ( þ 2.153). G-protein, a membrane-associated protein, mediates the effects of numerous G protein-coupled receptors including, metabotropic glutamate, dopamine, most serotonergic 5-HT, GABA B and neuropeptide receptors. In the post-mortem brain of schizophrenia patients, a greater response of adenylyl cyclase activity to fluoride stimulation of G proteins in the striatum and nucleus accumbens, missing G protein-mediated dopamine receptor D1-D2 link and reduced expression of subsets of G proteins in various brain regions was reported. 62 . In this study, the elevated level of a G protein subunit may represent increased binding of G protein coupled receptors, which may cause subsequent enhanced downstream cellular signalling with receptor candidates including dopamine, serotonin and glutamate receptors. 62 PEBP, or neuropolypeptide h3, is highly expressed in oligodendrocytes and nerve root Schwann cells 63 and to our knowledge this is the first study implicating PEBP in schizophrenia. The postulated functions of PEBP include organization of the plasma membrane during cell growth and development, regulating processes of the nervous system such as morphological changes of neural cells and a role in signalling, as well as being a precursor to the hippocampal cholinergic stimulating protein. 64 An increase of PEBP in the ACC gray matter in schizophrenia may represent enhanced activity of this protein, leading to various effects in this heterogeneous disease such as increased cholinergic output from the ACC, enhanced maintenance of neuronal processes and membrane organization, and increased proliferation and neuroprotection.
The increased levels of proteins involved in signal transduction suggests enhanced signalling in the schizophrenia ACC gray matter, causing various cellular effects including neuroprotection. The cause of this increase in specific signalling systems may be greater stimulation of neurotransmitter receptors, further implicating a role of ACC circuitry in schizophrenia.
Trafficking
A decrease in cerebral energy metabolism due to the reduced metabolic rate of glucose, together with neurotoxicity represent stress conditions capable of inducing heat shock proteins (HSP). 65 This molecular chaperone mediates folding and assembly of other proteins. HSP 70 was increased in the ACC gray matter proteome in schizophrenia. Subjects with schizophrenia have been reported to produce a high level of auto-antibodies to HSP70 which are reduced after 6 weeks of antipsychotic treatment. 32 The expression of antibodies to HSP in schizophrenia has been regarded as indicative of an autoimmune mechanism in the pathogenesis of schizophrenia, and may be involved in the neurodevelopmental susceptibility of the illness. 32 
Glial proteins
In the ACC gray matter proteome of schizophrenia, glial cell-specific proteins carbonic anhydrase and CKB show increased abundance, while GFAP and transferrin were decreased and absent, respectively. These results add further support to the involvement of glia in the pathophysiology of schizophrenia. 66, 67 Astrocytes provide structural and trophic support to neurons as well as having an important role in the immune response of the brain, synaptic function, clearance of cellular ions and transmitters, neuronal metabolism, neuronal migration and development and maintenance of the myelin sheath. 68 It is, therefore, postulated that an abnormality in any aspect of astrocytes may impact the integrity of the neuronal system. Oligodendrocytes share intercellular gap junctions only with astrocytes, therefore, a primary abnormality in either will most likely have an effect on the other and on myelination.
Studies into GFAP, a cytoskeletal marker of astroglia describe a reduction in GFAP protein levels. 19, 69 Webster et al. found a significant decrease in the levels of GFAP mRNA in the white matter underlying the ACC in subjects with Bipolar Disorder (BPD) and schizophrenia. 69 The gray matter also showed a reduction in GFAP mRNA with the most prominent change in layer VI, however, this did not reach statistical significance. 69 In this proteomic study, GFAP was reduced over 2.532 fold in schizophrenia, suggesting glial density is reduced in the cingulate cortex. This may be due to glial phenotypes unable to mount an appropriate reaction in the face of postmaturational infection or insult, or may be due to a prematurational problem in cell differentiation and migration. 69 This adds to the evidence that glial cells may be abnormal in subjects with schizophrenia indicating the inability of glia to mount a normal reaction to injury in the schizophrenia brain.
Confounding factors
Post-mortem examination has many possible confounding factors including PMI and pH. Cases were, therefore, matched for age, PMI and hemisphere to reduce these factors. Following post hoc statistical analysis, three proteins were found to have a positive correlation to either pH or PMI. The remaining 36 proteins altered in this study are most likely due to the disease. The possibility, however, that neuroleptics caused the alterations cannot be ruled out as all patients were medicated. As the neuroleptic dose was a wide range for most schizophrenia patients, Pearson correlations could not be performed. In addition, the effects of gender cannot be taken into consideration in this study as there were only two females in each group. Further studies are therefore warranted to examine the level of these proteins in other brain areas, in neuroleptic naive patients and animal models, patients with differing symptoms and genders. Furthermore, confirmation of these findings using alternative techniques such as immunohisotchemistry would also be beneficial in understanding the mechanisms underpinning schizophrenia. Finally, by assessing other neuropathological diseases the changes to proteins specifically due to schizophrenia can be determined.
Conclusions
Two-dimensional gel electrophoresis and MS were utilized to compare the ACC gray matter proteomes between schizophrenia and control post-mortem human tissue. A total of 39 proteins were identified at altered abundance, representing the products of 36 unique genes, which to our knowledge is the first proteomic analysis of the ACC in schizophrenia. Nine proteins are involved with metabolism, four associated with oxidative stress, nine relating to the cytoskeleton and three associated with the synapse. These findings are consistent with the literature detailing alterations in these functions within the ACC in schizophrenia. In addition, these results offer possible mechanisms of action in the pathogenesis of the disease and produce new and focussed directions for future studies.
